Related references
Note: Only part of the references are listed.Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma
Inna V. Fedorenko et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Validation of MdmX as a therapeutic target for reactivating p53 in tumors
Daniel Garcia et al.
GENES & DEVELOPMENT (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
High-Level Expression of Wild-Type p53 in Melanoma Cells is Frequently Associated with Inactivity in p53 Reporter Gene Assays
Roland Houben et al.
PLOS ONE (2011)
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Federico Bernal et al.
CANCER CELL (2010)
Mdm2-mediated ubiquitylation: p53 and beyond
J-C Marine et al.
CELL DEATH AND DIFFERENTIATION (2010)
Widespread Overexpression of Epitope-Tagged Mdm4 Does Not Accelerate Tumor Formation In Vivo
Sarah De Clercq et al.
MOLECULAR AND CELLULAR BIOLOGY (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Role of Mdm4 in drug sensitivity of breast cancer cells
S. Lam et al.
ONCOGENE (2010)
Differential roles of the pRb and Arf/p53 pathways in murine naevus and melanoma genesis
Blake Ferguson et al.
PIGMENT CELL & MELANOMA RESEARCH (2010)
p53-based Cancer Therapy
David P. Lane et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
Molecular Pathogenesis of Cutaneous Melanocytic Neoplasms
Nageatte Ibrahim et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2009)
MI-63: A novel small-molecule inhibitor targets MDM2 and induces apoptosis in embryonal and alveolar rhabdomyosarcoma cells with wild-type p53
J. A. Canner et al.
BRITISH JOURNAL OF CANCER (2009)
Blinded by the Light: The Growing Complexity of p53
Karen H. Vousden et al.
CELL (2009)
Tumor-specific induction of apoptosis by a p53-reactivating compound
Elisabeth Hedstrom et al.
EXPERIMENTAL CELL RESEARCH (2009)
Targeting Mdm2 and Mdmx in Cancer Therapy: Better Living through Medicinal Chemistry?
Mark Wade et al.
MOLECULAR CANCER RESEARCH (2009)
Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice
V. K. Goel et al.
ONCOGENE (2009)
Oncogenic NRAS Cooperates with p53 Loss to Generate Melanoma in Zebrafish
Michael Dovey et al.
ZEBRAFISH (2009)
Awakening guardian angels: drugging the p53 pathway
Christopher J. Brown et al.
NATURE REVIEWS CANCER (2009)
Immunohistochemical characteristics of melanoma
Steven J. Ohsie et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2008)
Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer
Sanieev Shangary et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype:: Lessons from recent developments in the IARC TP53 database
Audrey Petitjean et al.
HUMAN MUTATION (2007)
Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide
Federico Bernal et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2007)
Restoration of p53 function leads to tumour regression in vivo
Andrea Ventura et al.
NATURE (2007)
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Wen Xue et al.
NATURE (2007)
MDMX: from bench to bedside
Jean-Christophe W. Marine et al.
JOURNAL OF CELL SCIENCE (2007)
Modeling the therapeutic efficacy of p53 restoration in tumors
Carla P. Martins et al.
CELL (2006)
Regulating the p53 pathway:: in vitro hypotheses, in vivo veritas
Franck Toledo et al.
NATURE REVIEWS CANCER (2006)
Hdmx modulates the outcome of P53 activation in human tumor cells
Mark Wade et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Malignant melanoma: genetics and therapeutics in the genomic era
Lynda Chin et al.
GENES & DEVELOPMENT (2006)
Amplification of CDK4 and MDM2 in malignant melanoma
V Muthusamy et al.
GENES CHROMOSOMES & CANCER (2006)
Chemotherapy and targeted therapy combinations in advanced melanoma
KT Flaherty
CLINICAL CANCER RESEARCH (2006)
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to nutlin-3
JT Patton et al.
CANCER RESEARCH (2006)
Mdmx as an essential regulator of p53 activity
JC Marine et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background
J Ackermann et al.
CANCER RESEARCH (2005)
The role of B-RAF in melanoma
VC Gray-Schopfer et al.
CANCER AND METASTASIS REVIEWS (2005)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors
N Issaeva et al.
NATURE MEDICINE (2004)
Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity
D Danovi et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
The genetics of malignant melanoma: Lessons from mouse and man
L Chin
NATURE REVIEWS CANCER (2003)
Mdm4 (Mdmx) regulates p53-induced growth arrest and neuronal cell death during early embryonic mouse development
D Migliorini et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes
Jo Vandesompele et al.
GENOME BIOLOGY (2002)
Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer
J Jonkers et al.
NATURE GENETICS (2001)
Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma
A Demunter et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2001)
Dual inactivation of RB and p53 pathways in RAS-induced melanomas
N Bardeesy et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
